CLARIT Experiments in Batch Filtering: Term Selection and Threshold Optimization in IR and SVM Filters

The Clairvoyance team participated in the Filtering Track, submitting two runs in the Batch Filtering category. While we have been exploring the question of both topic modeling and ensemble filter construction (a

Supplementary Material, AUT689330_Lay_Abstract – Self-injurious behaviors in children with autism spectrum disorder enrolled in the Study to Explore Early Development

<p>Supplementary Material, AUT689330_Lay_Abstract for Self-injurious behaviors in children with autism spectrum disorder enrolled in the Study to Explore Early Development by Gnakub Norbert Soke, Steven A Rosenberg, Cordelia Robinson Rosenberg, Roma A Vasa, Li-Ching Lee and Carolyn DiGuiseppi in Autism</p

CLARIT Experiments in Batch Filtering:

Introduction The Clairvoyance team participated in the Filtering Track, submitting two runs in the Batch Filtering category. While we have been exploring the question of both topic modeling and ensemble filter construction (as in our previous TREC filtering experiments [5]), we had one distinct objective this year, to explore the viability of monolithic filters in classification-like tasks. This is appropriate to our work, in part, because monolithic filters are a crucial starting point for ensemble filtering, and it is possible for them to contribute substantially in the ensemble approach. Our primary goal in experiments this year, thus, was to explore two issues in monolithic filter construction: (1) term count selection and (2) filter threshold optimization. In fact, our pre-TREC experiments were conducted in a brief period and we were unable to complete all the tests we had planned. Our official submissions reflect essentially our first, baseline results. They are overall poor i

Supplemental Material - Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in <i>Komagataella phaffii</i>

Supplemental Material for Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii by Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, and Carrie-Anne Malinczak in International Journal of Toxicology</p

Supplemental Material - Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in <i>Komagataella phaffii</i>

Supplemental Material for Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii by Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, and Carrie-Anne Malinczak in International Journal of Toxicology</p

Supplemental Material - Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in <i>Komagataella phaffii</i>

Supplemental Material for Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii by Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, and Carrie-Anne Malinczak in International Journal of Toxicology</p

Rat hd Mutation Reveals an Essential Role of Centrobin in Spermatid Head Shaping and Assembly of the Head-Tail Coupling Apparatus1

The hypodactylous (hd) locus impairs limb development and spermatogenesis, leading to male infertility in rats. We show that the hd mutation is caused by an insertion of an endogenous retrovirus into intron 10 of the Cntrob gene. The retroviral insertion in hd mutant rats disrupts the normal splicing of Cntrob transcripts and results in the expression of a truncated protein. During the final phase of spermiogenesis, centrobin localizes to the manchette, centrosome, and the marginal ring of the spermatid acroplaxome, where it interacts with keratin 5-containing intermediate filaments. Mutant spermatids show a defective acroplaxome marginal ring and separation of the centrosome from its normal attachment site of the nucleus. This separation correlates with a disruption of head-tail coupling apparatus, leading to spermatid decapitation during the final step of spermiogenesis and the absence of sperm in the epididymis. Cntrob may represent a novel candidate gene for presently unexplained hereditary forms of teratozoospermia and the “easily decapitated sperm syndrome” in humans

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in african children

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries. Methods From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS,S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories. Results In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS,S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval [CI], 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS,S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64). Conclusions The RTS,S/AS01 vaccine provided protection against both clinical and severe malaria in African children. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619 .